

FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
M3S ↓	AA1	5,200,320	04/06/1993	Sette et al.	—	—	12/07/1987
	AB1	5,503,829	04/02/1996	Ladant et al.	—	—	11/07/1994
	AC1	5,585,461	12/17/1996	Townsend et al.	—	—	03/24/1994
	AD1	5,662,907	09/02/1997	Kubo et al.	—	—	01/25/1994
	AE1	6,034,214	03/07/2000	Boon et al.	—	—	12/13/1994
	AF1	6,077,519	06/20/2000	Storkus et al.	—	—	01/15/1997
	AG1	2002/0168374 A1	11/14/2002	Kubo et al.	—	—	03/20/1997
	AH1	2002/0177694 A1	11/28/2002	Sette et al.	—	—	02/03/1998
	AI						
	AJ						
AK							

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
M3S ↓	AL1	EP 0 044 710 A1	01/27/1982	Europe	—	—	Yes No
	AM1	EP 0 226 513 A1	06/24/1987	Europe	—	—	Yes X No
	AN1	WO 92/02543 A1	02/20/1992	WIPO	—	—	Yes No
	AO1	WO 92/12996 A2	08/06/1992	WIPO	—	—	Yes No
	AP1	WO 92/21033 A1	11/26/1992	WIPO	—	—	Yes X No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

M3S ↓	AR	1	Aichele, P., et al., "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> 171:1815-1820, Rockefeller University Press (1990)
	AS	1	Alexander, J., et al., "Derivation of HLA-A11/K <sup>b</sup> Transgenic Mice. Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," <i>J. Immunol.</i> 159:4753-4761, The American Association of Immunologists (November 1997)
	AT	1	Bergmann, C.C., et al., "Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides," <i>J. Virol.</i> 68:5306-5310, American Society for Microbiology (August 1994)

EXAMINER 	DATE CONSIDERED 3/5/06
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
MS	AL2	WO 93/03764 A1	03/04/1993	WIPO	—	—	Yes No
	AM2	WO 94/03205 A1	02/17/1994	WIPO	—	—	Yes No
	AN2	WO 94/11738 A1	05/26/1994	WIPO	—	—	Yes X No
	AO2	WO 94/20127 A1	09/15/1994	WIPO	—	—	Yes No
	AP2	WO 96/03140 A1	02/08/1996	WIPO	—	—	Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

MS	AR	<u>2</u>	Bertoni, R., et al., "Human Histocompatibility Leukocyte Antigen-binding Supermotifs Predict Broadly Cross-reactive Cytotoxic T Lymphocyte Responses in Patients with Acute Hepatitis," J. Clin. Invest. 100:503-513, The American Society for Clinical Investigation, Inc. (August 1997)
	AS	<u>2</u>	Bertoni, R., et al., "Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees," J. Immunol. 161:4447-4455, American Association of Immunologists (October 1998)
	AT	<u>2</u>	Bjorkman, P.J., et al., "Structure of the human class I histocompatibility antigen, HLA-A2," Nature 329:506-512, Macmillan Publishers, Ltd. (1987)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

VB	AR	3	Bjorkman, P.J., et al., "The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens," <i>Nature</i> 329:512-518, Macmillan Publishers, Ltd. (1987)
	AS	3	Buus, S., et al., "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia," <i>Science</i> 242:1045-1047, American Association for the Advancement of Science (1988)
	AT	3	Carreno, B.M., et al., "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> 87:3420-3424, National Academy Press (1990)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Corr, M., et al., "Endogenous Peptides of a Soluble Major Histocompatibility Complex Class I Molecule, H-2L <sup>d</sup> : Sequence Motif, Quantitative Binding, and Molecular Modeling of the Complex," J. Exp. Med. 176:1681-1692, Rockefeller University Press (December 1992)
	AS	<u>4</u>	De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," Eur. J. Immunol. 21:2963-2970, VCH Verlagsgesellschaft mbH (1991)
	AT	<u>4</u>	Del Val, M., et al., "Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on Its Neighboring Residues in the Protein," Cell 66:1145-1153, Cell Press (1991)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AB	AR	5	Deres, K., et al., "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," Nature 342:561-564, Macmillan Publishers, Ltd. (1989)
↓	AS	5	DiBrino, M., et al., "HLA-A1 and HLA-A3 T Cell Epitopes Derived from Influenza Virus Proteins Predicted from Peptide Binding Motifs," J. Immunol. 151:5930-5935, The Association of Immunologists (December 1993)
↓	AT	5	DiBrino, M., et al., "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," Proc. Natl. Acad. Sci. USA 90:1508-1512, National Academy Press (February 1993)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	6	Ding, Y.-H., et al., "Two Human T Cell Receptors Bind in a Similar Diagonal Mode to the HLA-A2/Tax Peptide Complex Using Different TCR Amino Acids," <i>Immunity</i> 8:403-11, Cell Press (April 1998)
	AS	6	Eisenlohr, L.C., et al., "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes," <i>J. Exp. Med.</i> 175:481-487, The Rockefeller University Press (February 1992)
	AT	6	Engelhard, V.H., "Structure of peptides associated with MHC Class I molecules," <i>Curr. Opin. Immunol.</i> 6:13-23, Current Biology, Ltd. (February 1994)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WBS	AR	2	Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351:290-296, Macmillan Publishers, Ltd. (1991)
	AS	2	Falk, K., et al., "MHC peptide motif register. Peptide motifs of HLA-B35 and -B37 molecules," <i>Immunogenetics</i> 38:161-162, Springer-Verlag (April 1993)
	AT	2	Falk, K., et al., "Allele-specific peptide ligand motifs of HLA-C molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:12005-12009, National Academy Press (December 1993)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Falk, K., et al., "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules," <i>Immunogenetics</i> 39:230-242, Springer-Verlag (February 1994)
	AS	8	Falk, K., et al., "Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules," <i>Immunogenetics</i> 40:238-241, Springer-Verlag (July 1994)
	AT	8	Foon, K.A., "Biological Response Modifiers: The New Immunotherapy," <i>Cancer Res.</i> 49:1621-1639, American Association for Cancer Research (1989)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

WBS	AR	2	Geysen, H.M., et al., "Cognitive Features of Continuous Antigenic Determinants," J. Mol. Recognit. 1:32-41, Heyden & Sons, Ltd. (1988)
↓	AS	2	Guo, H.-C., et al., "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle," Nature 360:364-366, Macmillan Publishers, Ltd. (November 1992)
↓	AT	2	Henderson, R.A., et al., "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," Science 255:1264-1266, American Association for the Advancement of Science (March 1992)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Hill, A., et al., "Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7," <i>Eur. J. Immunol.</i> 25:18-24, VCH Verlagsgesellschaft mbH (January 1995)
	AS	<u>10</u>	Hunt, D.F., et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263, American Association for the Advancement of Science (March 1992)
	AT	<u>10</u>	Ishioka, G.Y., et al., "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes," <i>J. Immunol.</i> 162:3915-3925, The American Association of Immunologists (April 1999)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Jameson, S.C., and Bevan, M.J., "Dissection of major histocompatibility complex (MHC) and T cell receptor contact residues in a K <sup>B</sup> -restricted ovalbumin peptide and an assessment of the predictive power of MHC-binding motifs," <i>Eur. J. Immunol.</i> 22:2663-2667, VCH Verlagsgesellschaft mbH (October 1992)
	AS	<u>11</u>	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329, Macmillan Publishers, Ltd. (1991)
	AT	<u>11</u>	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cells," <i>J. Virol.</i> 66:2928-2933, American Society for Microbiology (May 1992)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Kast, W.M., et al., "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy Press (1991)
	AS	<u>12</u>	Kast, W.M., et al., "Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination," <i>Eur. J. Immunol.</i> 23:1189-1192, VCH Verlagsgesellschaft mbH (May 1993)
	AT	<u>12</u>	Krieger, J.I., et al., "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition," <i>J. Immunol.</i> 146:2331-2340, American Association of Immunologists (1991)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Lipford, G.B., et al., "Primary in Vivo Responses to Ovalbumin. Probing the Predictive Value of the K <sup>b</sup> Binding Motif," J. Immunol. 150:1212-1222, The American Association of Immunologists (February 1993)
	AS	<u>13</u>	Maryanski, J.L., et al., "Synthetic peptides as antigens and competitors in recognition by H-2-restricted cytolytic T cells specific for HLA," J. Exp. Med. 167:1391-1405, Rockefeller University Press (1988)
	AT	<u>13</u>	Maryanski, J.L., et al., "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers," Cell 60:63-72, Cell Press (1990)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>14</u>	Morrison, J., et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 22:903-907, VCH Verlagsgesellschaft mbH (April 1992)
	AS	<u>14</u>	Niedermann, G., et al., "The proteolytic fragments generated by vertebrate proteosomes: Structural relationships to major histocompatibility complex class I binding peptides," <i>Proc. Natl. Acad. Sci. USA</i> 93:8572-8577, National Academy Press (August 1996)
	AT	<u>14</u>	Ochoa-Garay, J., et al., "The ability of peptides to induce cytotoxic T cells in vitro does not strongly correlate with their affinity for the H-2L <sup>d</sup> molecule: implications for vaccine design and immunotherapy," <i>Mol. Immunol.</i> 34:273-281, Elsevier Science, Ltd. (February 1997)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	15	Pamer, E.G., et al., "Precise prediction of a dominant class I MHC-restricted epitope of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855, Macmillan Publishers, Ltd. (1991)
	AS	15	Parham, P., et al., "The Origins of HLA-A,B,C Polymorphism," <i>Immunol. Rev.</i> 143:141-180, Munksgaard (February 1995)
	AT	15	Parker, K.C., et al., "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267:5451-5459, American Society for Biochemistry and Molecular Biology, Inc. (March 1992)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644


## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Parker, K.C., et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2," <i>J. Immunol.</i> 149:3580-3587, American Association of Immunologists (December 1992)
	AS	<u>16</u>	Rammensee, H.-G., et al., "Peptides Naturally Presented by MHC Class I Molecules," <i>Annu. Rev. Immunol.</i> 11:213-244, Annual Reviews, Inc. (January 1993)
	AT	<u>16</u>	Rammensee, H.-G., et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, Springer-Verlag (February 1995)

EXAMINER 	DATE CONSIDERED 8/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Reddehase, M.J., et al., "A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes," <i>Nature</i> 337:651-653, Macmillan Publishers, Ltd. (1989)
	AS	<u>17</u>	Romero, P., et al., "H-2K <sup>d</sup> -restricted Antigenic Peptides Share a Simple Binding Motif," <i>J. Exp. Med.</i> 174:603-612, Rockefeller University Press (1991)
	AT	<u>17</u>	Rothbard, J.B., "Major histocompatibility complex-peptide interactions," <i>Curr. Opin. Immunol.</i> 2:99-105, Current Biology, Ltd. (1989)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Röttschke, O., et al., "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254, Macmillan Publishers, Ltd. (1990)
	AS	<u>18</u>	Röttschke, O., et al., "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y," <i>Science</i> 249:283-287, American Association for the Advancement of Science (1990)
	AT	<u>18</u>	Röttschke, O., and Falk, K., "Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunol. Today</i> 12:447-455, Elsevier Science Publishers, Ltd. (1991)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>19</u>	Rotzschke, O., et al., "Peptide motifs of closely related HLA class I molecules encompass substantial differences," Eur. J. Immunol. 22:2453-2456, VCH Verlagsgesellschaft mbH (September 1992)
	AS	<u>19</u>	Röttschke, O., and Falk, K., "Origin, structure and motifs of naturally processed MHC class II ligands," Curr. Opin. Immunol. 6:45-51, Current Biology, Ltd. (February 1994)
	AT	<u>19</u>	Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in Peptide Hormones, Parsons, J.A., ed., University Park Press, Baltimore, MD, pp.1-7 (1976)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Ruppert, J., et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," Cell 74:929-937, Cell Press (September 1993)
	AS	<u>20</u>	Schulz, M., et al., "Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide," Eur. J. Immunol. 21:1181-1185, VCH Verlagsgesellschaft mbH (1991)
	AT	<u>20</u>	Sette, A., et al., "Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis," Proc. Natl. Acad. Sci. USA 86:3296-3300, National Academy Press (1989)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	21	Sette, A., et al., "Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules," <i>J. Immunol.</i> 147:3893-3900, The American Association of Immunologists (1991)
	AS	21	Sette, A., et al., "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-5592, The American Association of Immunologists (December 1994)
	AT	21	Shastri, N., et al., "Presentation of Endogenous Peptide/MHC Class I Complexes Is Profoundly Influenced by Specific C-Terminal Flanking Residues," <i>J. Immunol.</i> 155: 4339-4346, The American Association of Immunologists (November 1995)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Sherman, L.A., et al., "Extracellular Processing of Peptide Antigens That Bind Class I Major Histocompatibility Molecules," <i>J. Exp. Med.</i> 175:1221-1226, The Rockefeller University Press (May 1992)
	AS	<u>22</u>	Shimojo, N., et al., "Specificity of peptide binding by the HLA-A2.1 molecule," <i>J. Immunol.</i> 143:2939-2947, The American Association of Immunologists (1989)
	AT	<u>22</u>	Sidney, J., et al., "Several HLA Alleles Share Overlapping Peptide Specificities," <i>J. Immunol.</i> 154:247-259, The American Association of Immunologists (January 1995)

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>23</u>	Threlkeld, S.C., et al., "Degenerate and Promiscuous Recognition by CTL of Peptides Presented by the MHC Class I A3-like Superfamily. Implications for Vaccine Development," <i>J. Immunol.</i> 159:1648-1657, The American Association of Immunologists (August 1997)
	AS	<u>23</u>	Wentworth, P.A., et al., "Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice," <i>Eur. J. Immunol.</i> 26:97-101, VCH Verlagsgesellschaft mbH (January 1996)
	AT	<u>23</u>	Whitton, J.L., et al., "Molecular Analyses of a Five-Amino-Acid Cytotoxic T-Lymphocyte (CTL) Epitope: an Immunodominant Region Which Induces Nonreciprocal CTL Cross-Reactivity," <i>J. Virol.</i> 63:4303-4310, American Society for Microbiology (1989)

EXAMINER 	DATE CONSIDERED <u>3/5/01</u>
--	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

W37	AR	24	Yewdell, J.W., and Bennink, J.R., "Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes," <i>Adv. Immunol.</i> 52:1-123, Academic Press (July 1992)
	AS	24	York, I.A., and Rock, K.L., "Antigen processing and presentation by the class I major histocompatibility complex," <i>Annu. Rev. Immunol.</i> 14:369-396, Annual Reviews, Inc. (April 1996)
	AT	24	Zhang, Q-J., et al., "An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins," <i>Proc. Natl. Acad. Sci. USA</i> 90:2217-2221, National Academy Press (March 1993)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	25	Parker, K.C., et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," J. Immunol. 152:163-175, The American Association of Immunologists (January 1994)
	AS	25	<del>Dialog File 351, Accession No. 7180926, Derwent WPI English language abstract for EP 0 226 513.</del>
	AT	25	<del>Dialog File 351, Accession No. 9263567, Derwent WPI English language abstract for WO 92/21033.</del>

EXAMINER	DATE CONSIDERED 3/5/00
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

In compliance with citation MPEP 609-110

<b>FORM PTO-1449</b>  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	<b>ATTY. DOCKET NO.</b> 2060.0150002/HCC/PAC	<b>APPLICATION NO.</b> 09/583,200
	<b>APPLICANT</b> Fikes et al.	
	<b>FILING DATE</b> May 30, 2000	<b>GROUP</b> 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	26	<del>Dialog File 351, Accession No. 9888606. Derwent WPI English language abstract for WO 94/11738.</del>
<i>MS</i>	AS	26	Boel, P., et al., "BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes," <i>Immunity</i> 2:167-175, Cell Press (February 1995)
<i>MS</i>	AT	26	Boon, T., "Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy," <i>Intl. J. Cancer</i> 54:177-180, Wiley-Liss, Inc. (May 1993)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>27</u>	Brasseur, R., "Differentiation of Lipid-associating Helices by Use of Three-dimensional Molecular Hydrophobicity Potential Calculations," <i>J. Biol. Chem.</i> 266:16120-16127, The American Society for Biochemistry (1991)
	AS	<u>27</u>	Gambacorti-Passerini, C., et al., "Mapping of HLA Class I Binding Motifs in Forty-four Fusion Proteins Involved in Human Cancers," <i>Clin. Cancer Res.</i> 3:675-683, American Association for Cancer Research (May 1997)
	AT	<u>27</u>	Kamashima, I., et al., "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors," <i>Human Immunol.</i> 59:1-14, Elsevier Science Inc. (January 1998)

EXAMINER	DATE CONSIDERED 3/5/06
----------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
2060.0150002/HCC/PACAPPLICATION NO.  
09/583,200APPLICANT  
Fikes et al.FILING DATE  
May 30, 2000GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

mm	AR	28	Knuth, A., et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," <i>Curr. Opin. Immunol.</i> 3:659-664, Current Biology (1991)
	AS	28	Toes, R.E.M., et al., "Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells," <i>J. Immunol.</i> 160:4449-4456, The American Association of Immunologists (May 1998)
	AT	28	van der Bruggen, P., et al., "A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T Lymphocytes that recognize tumor cells expressing MAGE-3," <i>Eur. J. Immunol.</i> 24:3038-3043, VCH Verlagsgesellschaft mbH (December 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644




## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>29</u>	Copy of co-pending U.S. Patent Application 08/205,713, inventors Grey, H.M., filed March 4, 1994 <del>(NOT PUBLISHED)</del> .
	AS	<u>29</u>	Copy of co-pending U.S. Patent Application 08/344,824, inventors Sette, A. and Sidney, J., filed November 23, 1994 <del>(NOT PUBLISHED)</del> .
	AT	<u>29</u>	Copy of co-pending U.S. Patent Application 08/347,610, inventors Kubo et al., filed December 1, 1994 <del>(NOT PUBLISHED)</del> .

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <u>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE</u> <u>STATEMENT</u>	ATTY. DOCKET NO. 2060.0150002/HCC/PAC	APPLICATION NO. 09/583,200
	APPLICANT Fikes et al.	
	FILING DATE May 30, 2000	GROUP 1644



## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>30</u>	Copy of co-Pending U.S. Patent Application No. 08/452,843, inventors Sette, A. and Sidney, J., filed March 30, 1995 ( <del>NOT PUBLISHED</del> ).
	AS	<u>30</u>	Copy of co-Pending U.S. Patent Application No. 09/017,524, inventors Kubo et al., filed February 3, 1998 ( <del>NOT PUBLISHED</del> ).
	AT		

EXAMINER 	DATE CONSIDERED 3/5/06
--	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

*(use as many sheets as necessary)*

Sheet	1	of	3
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/583200
<b>Filing Date</b>	May 30, 2000
<b>First Named Inventor</b>	Fikes, John D
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	018623-015720US

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	3/4/06
-----------------------	--------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

SF 1269346 v1

RECEIVED

MAIL DATE CANCELLED  
SEP 27 2001

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO,

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete If Known

Application Number	09/583200
Filing Date	May 30, 2000
First Named Inventor	Fikes, John D
Group Art Unit	
Examiner Name	
Attorney Docket Number	018623-015720US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BS	AE	Bender, <i>et al.</i> "Improved Methods for the Generation of Dendritic Cells from Nonproliferating Progenitors in Human Blood" <i>J. of Immunological Methods</i> (1996) Vol. 196, pp. 121-135.	<input type="checkbox"/>
	AF	Celis, <i>et al.</i> "Epitope Selection and Development of Peptides Based Vaccines to Treat Cancer" <i>Cancer Biology</i> (1995) Vol. 6, pp. 329-336.	<input type="checkbox"/>
	AG	Celis, <i>et al.</i> "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five-Common HLA-A Alleles" <i>Molecular Immunology</i> (1994) Vol. 31(18), pp. 1423-1430.	<input type="checkbox"/>
	AH	Celis, <i>et al.</i> "Induction of Anti-tumor Cytotoxic T Lymphocytes in Normal Humans Using Primary Cultures and Synthetic Peptide Epitopes" <i>Proc. Natl. Acad. Sci.</i> (March 1994) Vol. 91, pp. 2105-2109.	<input type="checkbox"/>
	AI	Gaugler, <i>et al.</i> "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes" <i>Ludwig Institute for Cancer Research, Brussels Branch</i> (March 1994) Vol. 179(3), pp. 921-930.	<input type="checkbox"/>
	AJ	Kawakami, <i>et al.</i> "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression" <i>J. of Immunology</i> (1995) Vol. 154, pp. 3961-3968.	<input type="checkbox"/>
	AK	Kawashima, <i>et al.</i> "The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors" <i>Human Immunology</i> (1998) Vol. 59, pp. 1-14.	<input type="checkbox"/>
	AL	Nijman, <i>et al.</i> "p53, A Potential Target for Tumor-directed T Cells" <i>Immunology Letters</i> (1994) Vol. 40, pp. 171-178.	<input type="checkbox"/>
	AM	Parkhurst, <i>et al.</i> "Improved Induction of Melanoma-Reactive CTL with Peptide from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues" <i>J. of Immunology</i> (1996) pp. 2540-2547.	<input type="checkbox"/>
	AN	Ras, <i>et al.</i> "Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA)" <i>Human Immunology</i> (1997) Vol. 53, pp. 81-89.	<input type="checkbox"/>
	AO	Reynolds, <i>et al.</i> "HLA-Independent Heterogeneity of CD8 <sup>+</sup> T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients" <i>J. of Immunology</i> (1998) Vol. 161, pp. 6970-6976.	<input type="checkbox"/>

Examiner  
Signature

*[Signature]*

Date  
Considered

3/4/06


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1269346 v1

RECEIVED  
SEP 27 2001





Please type and sign inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

### Complete If Known

Application Number	09/583200
Filing Date	May 30, 2000
First Named Inventor	Fikes, John D
Group Art Unit	
Examiner Name	
Attorney Docket Number	018623-015720US

TECH CENTER 1500/2300  
SEP 27 2001

RECEIVED

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BS	AP	Rodriguez, <i>et al.</i> "Selective Transport of Internalized Antigens to the Cytosol for MHC Class I Presentation in Dendritic Cells" <i>Nature Cell Biology</i> (October 1999) Vol. 1, pp. 362-368.	<input type="checkbox"/>
	AQ	Rongcun, <i>et al.</i> "Identification of New HER2/ <i>neu</i> -Deived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogenic Carcinomas and Melanomas" <i>J. of Immunology</i> (1999) pp. 1037-1044.	<input type="checkbox"/>
	AR	Sette, <i>et al.</i> "HLA Supertypes and Supermotifs: A Functional Perspective on HLA Polymorphism" <i>Immunology</i> (1998) Vol. 10, pp. 478-482.	<input type="checkbox"/>
	AS	Sidney, <i>et al.</i> "Practical, Biochemical and Evolutionary Implications of the Discovery of HLA class I Supermotifs" <i>Immunology Today</i> (1996) Vol. 17(6), pp. 261-266.	<input type="checkbox"/>
	AT	Slingluff, <i>et al.</i> "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes is Mediated by at least Six Shared Peptide Epitopes" <i>J. of Immunology</i> (April 1993) Vol. 150(7), pp. 2955-2963.	<input type="checkbox"/>
	AU	Tsai, <i>et al.</i> "Identification of Subdominant CTL Epitopes of the gp100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells" <i>J. of Immunology</i> (1997) Vol. 158, pp. 1796-1802.	<input type="checkbox"/>
	AV	Watts, Colin "Dendritic Cells Spill the Beans" <i>Nature Cell Biology</i> (October 1999) Vol. 1, pp. E152-E154.	<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

3/4/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1269346 v1



FORM PTO-1449

ATTY. DOCKET NO.  
2060.0150002/HCC/PACAPPLICATION NO.  
09/583,200SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Fikes et al.FILING DATE  
May 30, 2000GROUP  
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AR		
	AS		
MS	AT	30	Copy of co-pending U.S. Patent Application No. 10/149,915, inventors Fikes et al., § 371 date October 15, 2002.

EXAMINER

DATE CONSIDERED 3/4/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.